Answers are grounded in this paper and cite their sources.
Chromatin remodeling controlled by histone methylation plays a key role in the regulation of PD-1/PD-L1 signaling, and histone demethylases participate in these delicate processes, including the regulation of PD-L1 in tumor cells or PD-1 in T cells. Histone demethylases are divided into two major families: the flavin adenine dinucleotide (FAD)-dependent KDM1 family and the Fe(II)/2-oxoglutarate-dependent JmjC-domain KDM family, and most of them regulate target genes in a demethylase activity-dependent manner. Their substrates are mainly methylated histone lysine residues, which control chromatin accessibility; a few are target proteins, which alter protein stability by demethylating several amino acid residues. The regulation of PD-1/PD-L1 mediated by histone demethylases is recognized as a potential mechanism underlying tumor immune evasion, which provides novel insights and potential therapeutic targets for clinical treatment of tumors. The antitumor effect of pharmacological intervention targeting histone demethylases with various small molecules or naturally active compounds has been reported, but its practical application in tumor immunotherapy remains very limited. This review systematically synthesizes mechanisms and translational evidence of histone demethylases in PD-1/PD-L1 regulation and cancer immunotherapy, resolving context-dependent findings and distinguishing preclinical efficacy from clinical validation.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: